Fluticasone Furoate is Used for relieving allergy symptoms such as nasal congestion, runny nose, sneezing, and itchy eyes in individuals aged 12 and up. It was first introduced by Glaxosmithkline in its drug Veramyst on Apr 27, 2007. Other drugs containing Fluticasone Furoate are Flonase Sensimist Allergy Relief, Arnuity Ellipta. 2 different companies have introduced drugs containing Fluticasone Furoate.

Fluticasone Furoate Patents

Given below is the list of patents protecting Fluticasone Furoate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Arnuity Ellipta	US5873360	Inhalation device	Feb 23, 2016 (Expired)	Glaxosmithkline
Arnuity Ellipta	US7101866	Anti-inflammatory androstane derivative	Aug 03, 2021 (Expired)	Glaxosmithkline
Arnuity Ellipta	US7629335	Anti-inflammatory androstane derivative	Aug 03, 2021 (Expired)	Glaxosmithkline
Arnuity Ellipta	US8113199	Counter for use with a medicament dispenser	Oct 23, 2027	Glaxosmithkline
Arnuity Ellipta	US8113199 (Pediatric)	Counter for use with a medicament dispenser	Apr 23, 2028	Glaxosmithkline
Arnuity Ellipta	US8161968	Medicament dispenser	Feb 05, 2028	Glaxosmithkline
Arnuity Ellipta	US8161968 (Pediatric)	Medicament dispenser	Aug 05, 2028	Glaxosmithkline
Arnuity Ellipta	US8201556	Medicament dispenser	Feb 05, 2029	Glaxosmithkline
Arnuity Ellipta	US8534281	Manifold for use in medicament dispenser	Mar 08, 2030	Glaxosmithkline
Arnuity Ellipta	US8534281 (Pediatric)	Manifold for use in medicament dispenser	Sep 08, 2030	Glaxosmithkline
Arnuity Ellipta	US8746242	Medicament dispenser	Oct 11, 2030	Glaxosmithkline
Arnuity Ellipta	US8746242 (Pediatric)	Medicament dispenser	Apr 11, 2031	Glaxosmithkline
Arnuity Ellipta	US9333310	Medicament dispenser	Oct 02, 2027	Glaxosmithkline
Arnuity Ellipta	US9333310 (Pediatric)	Medicament dispenser	Apr 02, 2028	Glaxosmithkline
Flonase Sensimist Allergy Relief	US6858596	Formulation containing anti-inflammatory androstane derivative	Aug 03, 2021 (Expired)	Haleon Us Holdings
Flonase Sensimist Allergy Relief	US7101866	Anti-inflammatory androstane derivative	Aug 03, 2021 (Expired)	Haleon Us Holdings
Flonase Sensimist Allergy Relief	US7541350	Formulation containing anti-inflammatory androstane derivative	Aug 03, 2021 (Expired)	Haleon Us Holdings
Flonase Sensimist Allergy Relief	US8062264	Fluid dispensing device	Apr 05, 2026	Haleon Us Holdings
Flonase Sensimist Allergy Relief	US8147461	Fluid dispensing device	Oct 15, 2028	Haleon Us Holdings
Flonase Sensimist Allergy Relief	US8347879	Fluid dispensing device	Jul 15, 2028	Haleon Us Holdings
Flonase Sensimist Allergy Relief	US8752543	Fluid dispensing device	Apr 05, 2026	Haleon Us Holdings
Flonase Sensimist Allergy Relief	US9320862	Fluid dispensing device	Nov 06, 2024	Haleon Us Holdings
Veramyst	US6858596	Formulation containing anti-inflammatory androstane derivative	Aug 03, 2021 (Expired)	Glaxosmithkline
Veramyst	US7101866	Anti-inflammatory androstane derivative	Aug 03, 2021 (Expired)	Glaxosmithkline
Veramyst	US7541350	Formulation containing anti-inflammatory androstane derivative	Aug 03, 2021 (Expired)	Glaxosmithkline
Veramyst	US8062264	Fluid dispensing device	Apr 05, 2026	Glaxosmithkline
Veramyst	US8147461	Fluid dispensing device	Mar 10, 2025	Glaxosmithkline
Veramyst	US8347879	Fluid dispensing device	Apr 01, 2027	Glaxosmithkline
Veramyst	US8752543	Fluid dispensing device	Apr 05, 2026	Glaxosmithkline
Veramyst	US9320862	Fluid dispensing device	Nov 06, 2024	Glaxosmithkline

Add above patents to watchlist

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳